secwatch.observer — SEC 8-K summary
======================================

Issuer:     Transcode Therapeutics, Inc. (RNAZ)
CIK:        0001829635
Form:       8-K
Filed at:   2023-05-10T23:59:59+00:00
Accession:  0001104659-23-058536
Event type: other_material
Sentiment:  neutral
Materiality: 0.60
Item codes: 5.07
LLM model:  deepseek-v4-flash:cloud@v2

TransCode shareholders approve reverse stock split, elect directors at 2023 annual meeting
--------------------------------------------------------------------------------

- Reverse stock split (ratio 1:2 to 1:20) approved: 9,104,123 for, 1,218,265 against, 124,718 abstain.
- All five director nominees elected: Dudley (6.99M), Calais (6.78M), Fitzgerald (6.74M), Marquet (6.79M), Manting (6.24M).
- Ratification of WithumSmith+Brown as auditor: 10,325,143 for, 83,468 against, 38,495 abstain.
- Adjournment proposal approved but not needed; sufficient votes existed for reverse split.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1829635/000110465923058536/0001104659-23-058536-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1829635/000110465923058536/tm2315296d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-23-058536

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer